Communiqués Medigene AG

Actions

MDG1

DE000A1X3W00

Marché Fermé - Xetra Autres places de cotation 17:36:06 06/06/2024			Varia. 5j.	Varia. 1 janv.
1,28 ^EUR	-4,12 %		+5,35 %	-16,07 %

21/05	Medigene et BioNTech prolongent leur partenariat dans le domaine de l'immunothérapie contre le cancer	MT
21/05	L'accord mondial de recherche et de collaboration entre Medigene AG et BioNTech SE se prolonge au-delà de la durée initiale annoncée	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Medigene AG Expands its End-to-End Platform by Submitting Three Development Optimization Technology Patents to the European Patent Office	28/05	GL
Medigene's Global Research & Collaboration Agreement with BioNTech to Extend Beyond Initially Announced Term	21/05	GL
Medigene : Description of the remuneration system for Supervisory Board members	17/05	PU
Medigene : Report of the Executive Board on agenda item 8	17/05	PU
Medigene : Report of the Executive Board on agenda item 9	17/05	PU
Medigene : Explanations of the rights of shareholders	17/05	PU
Medigene : Proxy to third person	17/05	PU
Medigene : Data protection information	17/05	PU
Medigene : CV Dr. Gerd Zettlmeissl	17/05	PU
Medigene Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS	15/05	GL
Medigene Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS	15/05	AQ
Medigene AG Extends Cash Runway into July 2025 After Successful Oversubscribed Capital Raise	14/05	GL
Medigene to Present at Upcoming Conferences	07/05	GL
Medigene AG Expands Patent Portfolio with European Patent Grant for its NY-ESO-1 targeted T Cell Receptor	03/05	AQ
Medigene AG Expands Patent Portfolio with European Patent Grant for its NY-ESO-1 – targeted T Cell Receptor	02/05	GL
Medigene Presents Superior TCR-T Cell Functionality by Inclusion of a Costimulatory Switch Protein	02/05	GL
Medigene : Quartely Statement 2024	26/04	PU
Medigene AG reports Financial Results and Business Update for Q1 2024	26/04	GL
Medigene presents streamlined 6-day, high stemness TCR-T therapy production process	25/04	GL
Medigene to Present at Upcoming Scientific Conferences	17/04	GL

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Medigene AG

Actions

MDG1

DE000A1X3W00

Communiqués

Filtres